Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Cancer Cell Retrieve available abstracts of 89 articles: HTML format

Single Articles

September 2024
1. XU J, Wan R, Cai Y, Cai S, et al
   Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.
   Cancer Cell. 2024;42:1598-1613.
   PubMed     Abstract available
   
   
   August 2024
2. MCRAE HM, Hargreaves DC
   Transcription factor dependencies identify BAF-dependent cancers.
   Cancer Cell. 2024;42:1326-1328.
   PubMed     Abstract available
   
   
   
3. HE T, Xiao L, Qiao Y, Klingbeil O, et al
   Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies.
   Cancer Cell. 2024;42:1336-1351.
   PubMed     Abstract available
   
   
   July 2024
4. DUPLAQUET L, So K, Ying AW, Pal Choudhuri S, et al
   Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer.
   Cancer Cell. 2024 Jul 17:S1535-6108(24)00237-X. doi: 10.1016/j.ccell.2024.
   PubMed     Abstract available
   
   
   June 2024
5. ZHOU Q, Pan Y, Yang X, Zhao Y, et al
   Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial.
   Cancer Cell. 2024 Jun 11:S1535-6108(24)00192-2. doi: 10.1016/j.ccell.2024.
   PubMed     Abstract available
   
   
   May 2024
6. MCGINNIS CS, Miao Z, Superville D, Yao W, et al
   The temporal progression of lung immune remodeling during breast cancer metastasis.
   Cancer Cell. 2024 May 24:S1535-6108(24)00167-3. doi: 10.1016/j.ccell.2024.
   PubMed     Abstract available
   
   
   
7. FINLAY JB, Ireland AS, Hawgood SB, Reyes T, et al
   Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer.
   Cancer Cell. 2024 May 20:S1535-6108(24)00164-8. doi: 10.1016/j.ccell.2024.
   PubMed     Abstract available
   
   
   
8. LIU SY, Feng WN, Wu YL
   Immunotherapy in resectable NSCLC: Answering the question or questioning the answer?
   Cancer Cell. 2024;42:727-731.
   PubMed     Abstract available
   
   
   March 2024
9. HU F, Lito P
   Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
   Cancer Cell. 2024;42:330-332.
   PubMed     Abstract available
   
   
   
10. HE XY, Gao Y, Ng D, Michalopoulou E, et al
    Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment.
    Cancer Cell. 2024;42:474-486.
    PubMed     Abstract available
    
    
    February 2024
11. TONG X, Patel AS, Kim E, Li H, et al
    Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Cancer Cell. 2024 Feb 20:S1535-6108(24)00036-9. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
12. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2024;42:318-322.
    PubMed    
    
    
    
13. HUANG DD, Yang JC
    Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
    Cancer Cell. 2024;42:172-174.
    PubMed     Abstract available
    
    
    
14. BENGUIGUI M, Cooper TJ, Kalkar P, Schif-Zuck S, et al
    Interferon-stimulated neutrophils as a predictor of immunotherapy response.
    Cancer Cell. 2024;42:253-265.
    PubMed     Abstract available
    
    
    
15. NABET BY, Hamidi H, Lee MC, Banchereau R, et al
    Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade.
    Cancer Cell. 2024 Feb 9:S1535-6108(24)00015-1. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    January 2024
16. HEEKE S, Gay CM, Estecio MR, Tran H, et al
    Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes.
    Cancer Cell. 2024 Jan 24:S1535-6108(24)00006-0. doi: 10.1016/j.ccell.2024.
    PubMed     Abstract available
    
    
    
17. MEMON D, Schoenfeld AJ, Ye D, Fromm G, et al
    Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
    Cancer Cell. 2024 Jan 9:S1535-6108(23)00441-5. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
18. CORDS L, Engler S, Haberecker M, Ruschoff JH, et al
    Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer.
    Cancer Cell. 2024 Jan 8:S1535-6108(23)00449-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    December 2023
19. ZHOU C, Hu Y, Arkania E, Kilickap S, et al
    A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
    Cancer Cell. 2023 Dec 21:S1535-6108(23)00432-4. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
20. DAYTON TL, Alcala N, Moonen L, den Hartigh L, et al
    Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
    Cancer Cell. 2023;41:2083-2099.
    PubMed     Abstract available
    
    
    
21. GERSTBERGER S, Ganesh K
    NEN in a dish: A patient-derived organoid biobank illuminates potential novel therapeutic opportunities for neuroendocrine neoplasms.
    Cancer Cell. 2023;41:2014-2016.
    PubMed     Abstract available
    
    
    
22. CHEN CC, Tran W, Song K, Sugimoto T, et al
    Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation.
    Cancer Cell. 2023;41:2066-2082.
    PubMed     Abstract available
    
    
    November 2023
23. JIAGGE E, Jin DX, Newberg JY, Perea-Chamblee T, et al
    Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers.
    Cancer Cell. 2023;41:1963-1971.
    PubMed     Abstract available
    
    
    
24. RAHAL Z, Kadara H
    Beyond bacteria: How the intratumor mycobiome modulates lung adenocarcinoma progression.
    Cancer Cell. 2023;41:1846-1848.
    PubMed     Abstract available
    
    
    October 2023
25. RODILLA AM, Valanparambil RM, Mack PC, Hsu CY, et al
    Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer.
    Cancer Cell. 2023 Oct 13:S1535-6108(23)00350-1. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
26. PAN Y, Zhang JT, Gao X, Chen ZY, et al
    Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients.
    Cancer Cell. 2023;41:1763-1773.
    PubMed     Abstract available
    
    
    
27. LI Z, Lu S
    Integrating minimal residual disease monitoring into clinical practice for NSCLC: Is the era upon us?
    Cancer Cell. 2023;41:1699-1701.
    PubMed     Abstract available
    
    
    September 2023
28. ZHU M, Kim J, Deng Q, Ricciuti B, et al
    Loss of p53 and mutational heterogeneity drives immune resistance in an autochthonous mouse lung cancer model with high tumor mutational burden.
    Cancer Cell. 2023 Sep 26:S1535-6108(23)00322-7. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
29. LIU NN, Yi CX, Wei LQ, Zhou JA, et al
    The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells.
    Cancer Cell. 2023 Sep 19:S1535-6108(23)00288-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
30. TOPP BG, Channavazzala M, Mayawala K, De Alwis DP, et al
    Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
    Cancer Cell. 2023;41:1680-1688.
    PubMed     Abstract available
    
    
    
31. MEGYESFALVI Z, Heeke S, Drapkin BJ, Solta A, et al
    Unfolding the secrets of small cell lung cancer progression: Novel approaches and insights through rapid autopsies.
    Cancer Cell. 2023;41:1535-1540.
    PubMed     Abstract available
    
    
    
32. CHEN K, Yang F, Shen H, Wang C, et al
    Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
    Cancer Cell. 2023 Sep 1:S1535-6108(23)00286-6. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    August 2023
33. HUANG Q, Liu L, Xiao D, Huang Z, et al
    CD44(+) lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration.
    Cancer Cell. 2023 Aug 9:S1535-6108(23)00252-0. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
34. DE MIGUEL FJ, Gentile C, Feng WW, Silva SJ, et al
    Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
    Cancer Cell. 2023 Aug 2:S1535-6108(23)00245-3. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    July 2023
35. QIAN Y, Galan-Cobo A, Guijarro I, Dang M, et al
    MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
    Cancer Cell. 2023;41:1363-1380.
    PubMed     Abstract available
    
    
    
36. PRIETO LI, Sturmlechner I, Graves SI, Zhang C, et al
    Senescent alveolar macrophages promote early-stage lung tumorigenesis.
    Cancer Cell. 2023;41:1261-1275.
    PubMed     Abstract available
    
    
    June 2023
37. MA BBY, Thu Le Q
    Hot on the trail in the TME: Clues from a trilogy of checkpoint inhibitor trials in nasopharyngeal cancer.
    Cancer Cell. 2023;41:1006-1008.
    PubMed     Abstract available
    
    
    May 2023
38. HASTON S, Gonzalez-Gualda E, Morsli S, Ge J, et al
    Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer.
    Cancer Cell. 2023 May 26:S1535-6108(23)00172-1. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
39. ZHOU L, Ruscetti M
    Senescent macrophages: A new "old" player in lung cancer development.
    Cancer Cell. 2023 May 20:S1535-6108(23)00175-7. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
40. ALLEN C, Santagata S
    Meet the authors: Dr. Clint Allen and Dr. Sandro Santagata.
    Cancer Cell. 2023;41:834-836.
    PubMed     Abstract available
    
    
    
41. WU Q, Hu G
    A genetic portrait of metastatic seeds in lung adenocarcinoma.
    Cancer Cell. 2023;41:828-830.
    PubMed     Abstract available
    
    
    
42. LENGEL HB, Mastrogiacomo B, Connolly JG, Tan KS, et al
    Genomic mapping of metastatic organotropism in lung adenocarcinoma.
    Cancer Cell. 2023;41:970-985.
    PubMed     Abstract available
    
    
    
43. GAGLIA G, Burger ML, Ritch CC, Rammos D, et al
    Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma.
    Cancer Cell. 2023;41:871-886.
    PubMed     Abstract available
    
    
    April 2023
44. WEEDEN CE, Gayevskiy V, Marceaux C, Batey D, et al
    Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer.
    Cancer Cell. 2023 Apr 13:S1535-6108(23)00092-2. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    
45. MOUSSET A, Lecorgne E, Bourget I, Lopez P, et al
    Neutrophil extracellular traps formed during chemotherapy confer treatment resistance via TGF-beta activation.
    Cancer Cell. 2023;41:757-775.
    PubMed     Abstract available
    
    
    
46. PAI JA, Hellmann MD, Sauter JL, Mattar M, et al
    Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade.
    Cancer Cell. 2023;41:776-790.
    PubMed     Abstract available
    
    
    March 2023
47. KLEMENT JD, Redd PS, Lu C, Merting AD, et al
    Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment.
    Cancer Cell. 2023;41:620-636.
    PubMed     Abstract available
    
    
    
48. MANGANA C, Maier BB
    A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade.
    Cancer Cell. 2023 Mar 10:S1535-6108(23)00048-X. doi: 10.1016/j.ccell.2023.
    PubMed     Abstract available
    
    
    February 2023
49. NILSSON MB, Yang Y, Heeke S, Patel SA, et al
    CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
    Cancer Cell. 2023;41:340-355.
    PubMed     Abstract available
    
    
    January 2023
50. PAN Y, Han H, Hu H, Wang H, et al
    KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition.
    Cancer Cell. 2023;41:88-105.
    PubMed     Abstract available
    
    
    December 2022
51. BALLESTEROS I, Cerezo-Wallis D, Hidalgo A
    Understanding NSCLC, one cell at a time.
    Cancer Cell. 2022;40:1459-1461.
    PubMed     Abstract available
    
    
    October 2022
52. SALCHER S, Sturm G, Horvath L, Untergasser G, et al
    High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.
    Cancer Cell. 2022 Oct 27. pii: S1535-6108(22)00499.
    PubMed     Abstract available
    
    
    
53. LAU SCM, Pan Y, Velcheti V, Wong KK, et al
    Squamous cell lung cancer: Current landscape and future therapeutic options.
    Cancer Cell. 2022 Oct 14. pii: S1535-6108(22)00480.
    PubMed     Abstract available
    
    
    
54. SKOULIDIS F, Heymach JV, Cascone T
    A STING operation to expose KRAS and STK11 co-mutated lung cancers.
    Cancer Cell. 2022;40:1073-1076.
    PubMed     Abstract available
    
    
    
55. MUKHERJEE S, Carrot-Zhang J
    Whole-genome sequencing of East Asian lung cancers reveals new germline pathogenic variants.
    Cancer Cell. 2022;40:1081-1083.
    PubMed     Abstract available
    
    
    
56. NASSAR AH, Adib E, Abou Alaiwi S, El Zarif T, et al
    Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors.
    Cancer Cell. 2022;40:1161-1172.
    PubMed     Abstract available
    
    
    September 2022
57. KITAJIMA S, Tani T, Springer BF, Campisi M, et al
    MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer.
    Cancer Cell. 2022 Sep 18. pii: S1535-6108(22)00379.
    PubMed     Abstract available
    
    
    
58. LEUNG CSK, Van den Eynde BJ
    Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC.
    Cancer Cell. 2022;40:903-905.
    PubMed     Abstract available
    
    
    August 2022
59. WANG C, Dai J, Qin N, Fan J, et al
    Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese.
    Cancer Cell. 2022 Aug 30. pii: S1535-6108(22)00377.
    PubMed     Abstract available
    
    
    
60. AWAD MM, Govindan R, Balogh KN, Spigel DR, et al
    Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
    Cancer Cell. 2022 Aug 17. pii: S1535-6108(22)00359.
    PubMed     Abstract available
    
    
    
61. MURPHY BM, Burd CE
    The aging lung microenvironment awakens melanoma metastases.
    Cancer Cell. 2022;40:815-817.
    PubMed     Abstract available
    
    
    July 2022
62. ELAMIN YY, Robichaux JP, Carter BW, Altan M, et al
    Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
    Cancer Cell. 2022;40:754-767.
    PubMed     Abstract available
    
    
    
63. CARDONA AF, Gonzalez-Cao M, Arrieta O, Rosell R, et al
    Location of EGFR exon 20 insertions matters.
    Cancer Cell. 2022;40:705-708.
    PubMed     Abstract available
    
    
    May 2022
64. HERBST RS, Wang M, Chen L
    When immunotherapy meets surgery in non-small cell lung cancer.
    Cancer Cell. 2022 May 31. pii: S1535-6108(22)00221.
    PubMed     Abstract available
    
    
    
65. HANADA KI, Zhao C, Gil-Hoyos R, Gartner JJ, et al
    A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.
    Cancer Cell. 2022;40:479-493.
    PubMed     Abstract available
    
    
    April 2022
66. MACK PC, Gomez JE, Rodilla AM, Carreno JM, et al
    Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer.
    Cancer Cell. 2022 Apr 20. pii: S1535-6108(22)00174.
    PubMed    
    
    
    February 2022
67. TEILLAUD JL, Dieu-Nosjean MC
    Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?
    Cancer Cell. 2022 Feb 22. pii: S1535-6108(22)00060.
    PubMed     Abstract available
    
    
    
68. PATIL NS, Nabet BY, Muller S, Koeppen H, et al
    Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer.
    Cancer Cell. 2022 Feb 22. pii: S1535-6108(22)00035.
    PubMed     Abstract available
    
    
    January 2022
69. COOPER AJ, Sequist LV, Johnson TW, Lin JJ, et al
    LTK fusions: A new target emerges in non-small cell lung cancer.
    Cancer Cell. 2022;40:23-25.
    PubMed     Abstract available
    
    
    
70. NEWELL F, Pires da Silva I, Johansson PA, Menzies AM, et al
    Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
    Cancer Cell. 2022;40:88-102.
    PubMed     Abstract available
    
    
    November 2021
71. YENERALL P, Kittler R, Minna J
    Structure-based classification of EGFR mutations informs inhibitor selection for lung cancer therapy.
    Cancer Cell. 2021;39:1455-1457.
    PubMed     Abstract available
    
    
    
72. LEADER AM, Grout JA, Maier BB, Nabet BY, et al
    Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification.
    Cancer Cell. 2021 Nov 2. pii: S1535-6108(21)00560.
    PubMed     Abstract available
    
    
    October 2021
73. CHAN JM, Quintanal-Villalonga A, Gao VR, Xie Y, et al
    Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer.
    Cancer Cell. 2021 Oct 12. pii: S1535-6108(21)00497.
    PubMed     Abstract available
    
    
    September 2021
74. HU H, Piotrowska Z, Hare PJ, Chen H, et al
    Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.
    Cancer Cell. 2021 Sep 28. pii: S1535-6108(21)00492.
    PubMed     Abstract available
    
    
    
75. LE X, Nilsson MB, Robichaux JP, Heymach JV, et al
    ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
    Cancer Cell. 2021;39:1178-1180.
    PubMed     Abstract available
    
    
    
76. ZHOU Q, Xu CR, Cheng Y, Liu YP, et al
    Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
    Cancer Cell. 2021;39:1279-1291.
    PubMed     Abstract available
    
    
    August 2021
77. MOORE AR, Malek S
    The promise and peril of KRAS G12C inhibitors.
    Cancer Cell. 2021;39:1059-1061.
    PubMed     Abstract available
    
    
    
78. PE'ER D, Ogawa S, Elhanani O, Keren L, et al
    Tumor heterogeneity.
    Cancer Cell. 2021;39:1015-1017.
    PubMed     Abstract available
    
    
    
79. PEARSON JD, Huang K, Pacal M, McCurdy SR, et al
    Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity.
    Cancer Cell. 2021;39:1115-1134.
    PubMed     Abstract available
    
    
    
80. GARLANDA C, Mantovani A
    Interleukin-1 in tumor progression, therapy, and prevention.
    Cancer Cell. 2021;39:1023-1027.
    PubMed     Abstract available
    
    
    July 2021
81. TANAKA K, Yu HA, Yang S, Han S, et al
    Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis.
    Cancer Cell. 2021 Jul 27. pii: S1535-6108(21)00383.
    PubMed     Abstract available
    
    
    May 2021
82. KLEIN O, Kee D, Markman B, Carlino MS, et al
    Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
    Cancer Cell. 2021;39:592-593.
    PubMed    
    
    
    April 2021
83. DRAPKIN BJ, Minna JD
    A rational targeted therapy for platinum-resistant small-cell lung cancer.
    Cancer Cell. 2021;39:453-456.
    PubMed     Abstract available
    
    
    
84. THOMAS A, Takahashi N, Rajapakse VN, Zhang X, et al
    Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
    Cancer Cell. 2021;39:566-579.
    PubMed     Abstract available
    
    
    March 2021
85. KOS K, de Visser KE
    Neutrophils create a fertile soil for metastasis.
    Cancer Cell. 2021;39:301-303.
    PubMed     Abstract available
    
    
    
86. SANCLEMENTE M, Nieto P, Garcia-Alonso S, Fernandez-Garcia F, et al
    RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
    Cancer Cell. 2021;39:294-296.
    PubMed    
    
    
    
87. GAY CM, Stewart CA, Park EM, Diao L, et al
    Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.
    Cancer Cell. 2021;39:346-360.
    PubMed     Abstract available
    
    
    February 2021
88. SRIVASTAVA S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, et al
    Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
    Cancer Cell. 2021;39:193-208.
    PubMed     Abstract available
    
    
    December 2020
89. XIAO Y, Cong M, Li J, He D, et al
    Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation.
    Cancer Cell. 2020 Dec 31. pii: S1535-6108(20)30660.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.